Results 181 to 190 of about 74,938 (343)

La PME tunisienne

open access: yes, 2022
Denieuil, Pierre-Noël   +2 more
openaire   +1 more source

A Biweekly GLP‐1R Agonist Designed With Drug‐Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To develop a next‐generation, longer‐acting, more‐clinical‐benefits agonist to achieve sustained efficacy with improved tolerability. Methods CT130 was designed from semaglutide. Binding affinity was validated via molecular dynamics and cellular assays.
Wei Ding   +4 more
wiley   +1 more source

Iloperidone treatment mitigates the Juvenile Huntington's Disease phenotype possibly via Sigma‐1 Receptor Modulation

open access: yesThe FEBS Journal, EarlyView.
We investigated the potential of iloperidone as an activator of Sigma‐1 receptor (S1R) neuroprotective function in juvenile Huntington's disease (jHD). We tested iloperidone on cortical neurons differentiated from patient‐derived iPSCs, demonstrating that it acts as a S1R agonist, decreasing apoptosis, huntingtin aggregation, and oxidative stress ...
Ersilia Fornetti   +11 more
wiley   +1 more source

Molecular dynamics simulations and fluorescence spectroscopy suggest reduced tryptophan‐to‐heme energy transfer facilitates lignin degradation in ClassII peroxidases

open access: yesThe FEBS Journal, EarlyView.
In lignin peroxidase and versatile peroxidase, low FRET from buried Trp to heme promotes long‐range electron transfer (LRET) from substrate to heme. This efficient electron flow is facilitated by reduced FRET competition. This mechanism likely evolved to enable the effective degradation of bulky, high‐redox‐potential lignin that cannot reach the enzyme'
Yi Ren   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy